Closing of Series B-2 Stock Offering

SpineThera, a privately held, pre-clinical stage pharmaceutical company, announced the closing of a $2.81M preferred stock offering. SpineThera Founder and CEO, Jeff Missling, said, "With support from both existing and new investors, I am pleased to announce the closing of our Series B-2 stock offering. Raising this additional capital will enable us to aggressively pursue further development of our patented micro-suspension, sustained-release corticosteroid for epidural administration to treat back pain."